Literature DB >> 28602012

Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease.

Panagiotis Alexopoulos1,2, Lena-Sophie Gleixner3, Lukas Werle3,4, Felix Buhl3, Nathalie Thierjung3, Evangelia Giourou5, Simone M Kagerbauer6, Philippos Gourzis5, Hubert Kübler7, Timo Grimmer3, Igor Yakushev8, Jan Martin6, Alexander Kurz3, Robert Perneczky9,10,11,12.   

Abstract

The established biomarkers of Alzheimer's disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate.

Entities:  

Keywords:  Biomarker-underpinned diagnoses; Dementia due to Alzheimer’s disease; FDG-PET; Mild cognitive impairment; Soluble amyloid precursor protein β (sAPPβ); Upstream biomarkers

Mesh：

Substances：

Year:  2017        PMID： 28602012     DOI： 10.1007/s00406-017-0815-9

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN： 0940-1334            Impact factor:   5.270


  35 in total

1.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

2.  Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease.

Authors:  Panagiotis Alexopoulos; Laura Kriett; Bernhard Haller; Elisabeth Klupp; Katherine Gray; Timo Grimmer; Nikolaos Laskaris; Stefan Förster; Robert Perneczky; Alexander Kurz; Alexander Drzezga; Andreas Fellgiebel; Igor Yakushev
Journal:  Alzheimers Dement       Date:  2014-05-22       Impact factor: 21.566

3.  Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

Authors:  F Hulstaert; K Blennow; A Ivanoiu; H C Schoonderwaldt; M Riemenschneider; P P De Deyn; C Bancher; P Cras; J Wiltfang; P D Mehta; K Iqbal; H Pottel; E Vanmechelen; H Vanderstichele
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

4.  Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Authors:  Tobias Skillbäck; Bahman Y Farahmand; Christoffer Rosén; Niklas Mattsson; Katarina Nägga; Lena Kilander; Dorota Religa; Anders Wimo; Bengt Winblad; Jonathan M Schott; Kaj Blennow; Maria Eriksdotter; Henrik Zetterberg
Journal:  Brain       Date:  2015-06-30       Impact factor: 13.501

5.  Is the word 'biomarker' being properly used by proteomics research in neuroscience?

Authors:  Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-14       Impact factor: 5.270

Review 6.  The New Conceptualization of Alzheimer's Disease under the Microscope of Influential Definitions of Disease.

Authors:  Panagiotis Alexopoulos; Alexander Kurz
Journal:  Psychopathology       Date:  2015-11-27       Impact factor: 1.944

7.  Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.

Authors:  Panagiotis Alexopoulos; Jennifer Roesler; Nathalie Thierjung; Lukas Werle; Dorothea Buck; Igor Yakushev; Lena Gleixner; Simone Kagerbauer; Marion Ortner; Timo Grimmer; Hubert Kübler; Jan Martin; Nikolaos Laskaris; Alexander Kurz; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-08       Impact factor: 5.270

8.  Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects.

Authors:  Guoxin Wu; Sethu Sankaranarayanan; Kate Tugusheva; Jason Kahana; Guy Seabrook; Xiao-Ping Shi; Elizabeth King; Viswanath Devanarayan; Jacquelynn J Cook; Adam J Simon
Journal:  Clin Biochem       Date:  2008-05-06       Impact factor: 3.281

9.  Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.

Authors:  Alex E Roher; Chera L Esh; Tyler A Kokjohn; Eduardo M Castaño; Gregory D Van Vickle; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Ian D Daugs; Yu-Min Kuo; Mark R Emmerling; Holly Soares; Joseph F Quinn; Jeffrey Kaye; Donald J Connor; Nina B Silverberg; Charles H Adler; James D Seward; Thomas G Beach; Marwan N Sabbagh
Journal:  Alzheimers Dement       Date:  2009-01       Impact factor: 21.566

Review 10.  (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Shuo Zhang; Nadja Smailagic; Chris Hyde; Anna H Noel-Storr; Yemisi Takwoingi; Rupert McShane; Juan Feng
Journal:  Cochrane Database Syst Rev       Date:  2014-07-23
View more
  2 in total

1.  Regressive Autism Spectrum Disorder: High Levels of Total Secreted Amyloid Precursor Protein and Secreted Amyloid Precursor Protein-α in Plasma.

Authors:  Xiaoli Li; Ping Zhou; Qiu Li; Bin Peng; Yupeng Cun; Ying Dai; Hua Wei; Xiao Liu; Yang Yu; Zhiyang Jiang; Qiongli Fan; Yuping Zhang; Ting Yang; Jie Chen; Qian Cheng; Tingyu Li; Li Chen
Journal:  Front Psychiatry       Date:  2022-03-08       Impact factor: 4.157

Review 2.  Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.

Authors:  Sonia Mayo; Julián Benito-León; Carmen Peña-Bautista; Miguel Baquero; Consuelo Cháfer-Pericás
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.